KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Equity Ratio (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Equity Ratio for 6 consecutive years, with 0.77 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio rose 7.39% year-over-year to 0.77, compared with a TTM value of 0.77 through Dec 2025, up 7.39%, and an annual FY2025 reading of 0.77, up 7.39% over the prior year.
  • Equity Ratio was 0.77 for Q4 2025 at Recursion Pharmaceuticals, up from 0.75 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.92 in Q2 2021 and bottomed at 0.86 in Q1 2021.
  • Average Equity Ratio over 5 years is 0.66, with a median of 0.71 recorded in 2024.
  • The sharpest move saw Equity Ratio soared 228.76% in 2021, then crashed 30.24% in 2022.
  • Year by year, Equity Ratio stood at 0.89 in 2021, then fell by 22.13% to 0.69 in 2022, then rose by 2.34% to 0.71 in 2023, then increased by 0.76% to 0.71 in 2024, then rose by 7.39% to 0.77 in 2025.
  • Business Quant data shows Equity Ratio for RXRX at 0.77 in Q4 2025, 0.75 in Q3 2025, and 0.71 in Q2 2025.